Journal of cancer research updates最新文献_第7页

Early Phase I Results for 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] as Therapy in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies 4-去甲基-4-胆固醇氧基苯科米定[dm - choco - pen]治疗晚期恶性肿瘤的青少年和青年(AYA)受试者的早期I期研究结果

Journal of cancer research updates Pub Date : 2018-06-25 DOI: 10.6000/1929-2279.2018.07.03.2

L. Morgan, R. Weiner, M. Ware, M. Bhandari, T. Mahmood, P. Friedlander

{"title":"Early Phase I Results for 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] as Therapy in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies","authors":"L. Morgan, R. Weiner, M. Ware, M. Bhandari, T. Mahmood, P. Friedlander","doi":"10.6000/1929-2279.2018.07.03.2","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.03.2","url":null,"abstract":"4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine carbonate with a MOA via bis -alkylation of DNA @ N 7 -guanine and N 4 -cytosine that has completed adult clinical Phase I and II trials in individuals with malignancies involving the CNS. We report here objective clinical observations seen in a clinical Phase I DM-CHOC-PEN trial with AYA subjects that have cancer (some of which had CNS involvement). Subjects & Methods : DM-CHOC-PEN was administered as a single 3-hr IV infusion once every 21 days in escalating doses from 50 – 98.7 mg/m 2 to individuals (aged 15-39 years of age) with advanced malignancies. Results : Twelve (12) AYA individuals have been treated to date (with or without CNS involvement). The drug was well tolerated with fatigue (17%) being the most common adverse effect. No neuro/cognitive, liver dysfunction, hematological, cardiac, renal or GI toxicities were observed. Pharmacokinetic profiling revealed higher AUCs for all dose levels (50-98.7 mg/m 2 ) than had been seen previously in adults. Three (3) AYA individuals treated (1 each with NSCLC, ALL, and astrocytoma involving the CNS) have responded with CR/PR (RECIST 1.1), improved QOL/PFS (Kaplan-Meier) and OS from 8 to 35+ mos. Conclusion : DM-CHOC-PEN is safe in doses of 50-98.7 mg/m 2 and produced objective responses with improved OS and manageable toxicities in AYA individuals with malignancies involving the CNS. Complete data on subject responses and observed toxicities will be presented. The data support a 3-stage mechanism for tumor cytotoxicity: entry into the CNS and into the tumor via reversible binding to RBC membranes; then transported into cancer cells with L-glutamine; and bis -alkylation as described above.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48038039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do we Need to Wake Patients up during Cortical Surgery? 在皮质手术中我们需要叫醒病人吗?

Journal of cancer research updates Pub Date : 2018-06-25 DOI: 10.6000/1929-2279.2018.07.03.4

L. Zelaya, R. Sola, P. Pulido, J. Pastor

{"title":"Do we Need to Wake Patients up during Cortical Surgery?","authors":"L. Zelaya, R. Sola, P. Pulido, J. Pastor","doi":"10.6000/1929-2279.2018.07.03.4","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.03.4","url":null,"abstract":"In recent years, a renewed fashion for awake surgery has appeared. In spite of its undoubted utility for scientific research, this technique has several limitations and flaws, usually not debated by parts of the scientific community. We will discuss the aims and limitations of cortical surgery, especially the points relevant to protecting the patient. These objectives should define the guidelines that direct clinical practice. We will review the awake technique as well as various tools used in intraoperative neurophysiological monitoring (IONM) to explore and monitor several cortical functions during long surgeries. The main topics discussed include electrocorticography (ECoG) and cortically recorded evoked potentials (EP), including somatosensory, visual and auditory. Later, we will discuss methods to identify and survey motor functions as motor-evoked potentials, although they are elicited trans-cranially. Finally, we will briefly discuss a promising technique to monitor some language functions in anaesthetized patients, such as cortico-cortical evoked potentials (CCEP). We will address in depth some technical questions about electrical stimulation whose full relevance are not always considered. Finally, we will discuss why, in the absence of empirical facts showing unequivocal superiority in post-surgical outcome, we have to awaken patients, especially when an alternate possibility exists without worst clinical results, as is the case for IONM.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42432349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Aberrant DNA damage response and DNA repair pathway in high glucose conditions. 高糖条件下异常的DNA损伤反应和DNA修复途径。

Journal of cancer research updates Pub Date : 2018-06-25 DOI: 10.6000/1929-2279.2018.07.03.1

Amy Zhong, Melissa H Y Chang, T-H Yu, Raymond Gau, D. Riley, Yumay Chen, Phang-lang Chen

{"title":"Aberrant DNA damage response and DNA repair pathway in high glucose conditions.","authors":"Amy Zhong, Melissa H Y Chang, T-H Yu, Raymond Gau, D. Riley, Yumay Chen, Phang-lang Chen","doi":"10.6000/1929-2279.2018.07.03.1","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.03.1","url":null,"abstract":"Background\u0000Higher cancer rates and more aggressive behavior of certain cancers have been reported in populations with diabetes mellitus. This association has been attributed in part to the excessive reactive oxygen species generated in diabetic conditions and to the resulting oxidative DNA damage. It is not known, however, whether oxidative stress is the only contributing factor to genomic instability in patients with diabetes or whether high glucose directly also affects DNA damage and repair pathways.\u0000\u0000\u0000Results\u0000Normal renal epithelial cells and renal cell carcinoma cells are more chemo- and radiation resistant when cultured in high concentrations of glucose. In high glucose conditions, the CHK1-mediated DNA damage response is not activated properly. Cells in high glucose also have slower DNA repair rates and accumulate more mutations than cells grown in normal glucose concentrations. Ultimately, these cells develop a transforming phenotype.\u0000\u0000\u0000Conclusions\u0000In high glucose conditions, defective DNA damage responses most likely contribute to the higher mutation rate in renal epithelial cells, in addition to oxidative DNA damage. The DNA damage and repair are normal enzyme dependent mechanisms requiring euglycemic environments. Aberrant DNA damage response and repair in cells grown in high glucose conditions underscore the importance of maintaining good glycemic control in patients with diabetes mellitus and cancer.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 3 1","pages":"64-74"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44072201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML 费城染色体阳性CML的药物治疗选择

Journal of cancer research updates Pub Date : 2018-05-17 DOI: 10.6000/1929-2279.2018.07.02.3

Atish Patel, Hui Zhang, Deshen Wang, Dong-Hua Yang, Sanjay L. Dholakiya, Zhe-Sheng Chen

{"title":"Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML","authors":"Atish Patel, Hui Zhang, Deshen Wang, Dong-Hua Yang, Sanjay L. Dholakiya, Zhe-Sheng Chen","doi":"10.6000/1929-2279.2018.07.02.3","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.02.3","url":null,"abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cells. Identifying the leading mutation in BCR-ABL that causes CML made it possible to develop a targeted approach against this vastly disseminating disease. The active tyrosine kinase protein of BCR-ABL was effectively blocked with an identified tyrosine kinase inhibitor (TKI), imatinib. Imatinib became the first targeted therapy licensed for patients with chronic-phase CML and its introduction was associated with substantial improvements in response and survival compared with previous therapies. However, drug resistance towards imatinib therapy soon emerged and hence limited the complete eradication of CML in patients receiving imatinib. This is primarily due to the mutations within the ABL kinase domain, and to a lesser degree, due to residual disease after treatment. Nilotinib and dasatinib were soon introduced and showed improved clinical outcomes in patients intolerant and resistant to imatinib treatment. However, the T315I mutant overcame these agents along with imatinib, rendering the treatment ineffective. Exploring the kinase domain of the BCR-ABL protein and identifying key components involved in the signal transduction pathways is crucial towards understanding the disease and developing better strategic approaches towards combating it. In this review, we broadly discuss the current treatment options available against Philadelphia chromosome (Ph) positive BCR-ABL CML.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 1","pages":"49-58"},"PeriodicalIF":0.0,"publicationDate":"2018-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45708017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

About a Rare Case of Low-Grade Chondrosarcoma of the Cranial Vault 颅顶低级别软骨肉瘤1例报道

Journal of cancer research updates Pub Date : 2018-05-17 DOI: 10.6000/1929-2279.2018.07.02.1

L. Tacconi, G. D’acunzi, C. Russo, A. Manto, R. Fristachi

引用次数: 0

Study of the Prevalence and the Incidence of the Prostate Cancer in the North-Cameroon: Means and Costs of Management 喀麦隆北部前列腺癌患病率和发病率的研究:管理的手段和成本

Journal of cancer research updates Pub Date : 2018-05-17 DOI: 10.6000/1929-2279.2018.07.02.2

Herve Kada Pabame, A. H. N. Kamdje, R. Simo, Franklin Danki Sillong

{"title":"Study of the Prevalence and the Incidence of the Prostate Cancer in the North-Cameroon: Means and Costs of Management","authors":"Herve Kada Pabame, A. H. N. Kamdje, R. Simo, Franklin Danki Sillong","doi":"10.6000/1929-2279.2018.07.02.2","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.02.2","url":null,"abstract":"Introduction : The high mortality rate of prostate cancer in Cameroon, its high incidence, its prevalence, the lack of epidemiological data for the north which for the case is the poorest area of the country led us to conduct this study with for the purpose of presenting the epidemiological, clinical and para-clinical aspects, the cost and means of management with a view to setting up adequate management policies. Patients and Methods : We conducted a cross-sectional analytical study in the city of Ngaoundere for a period of 5 months. The data were obtained after a survey of patients and collection of results from the pathology registry of the Islamic clinic of Adamawa three months before the start of our study. Results : The prevalence and incidence of prostate cancer were 28.7% and 24.32%, respectively. The average age of prostate cancer patients was 66.5 years. Gleason scores were less than 6 in 44.44% of cases. Risk factors related to familial cancer cases were difficult to determine. The symptoms were dominated in patients by urinary retention associated with polyuria, dysuria and pollakiuria. The means and costs of care were scalable depending on the difficulty of achieving the technique. Conclusion : Prostate cancer remains a real health problem in the north because of its incidence and high prevalence and requires the implementation of a government policy of care.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 1","pages":"41-48"},"PeriodicalIF":0.0,"publicationDate":"2018-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43933420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sildenafil Induces Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer HT-29 Cells 西地那非诱导人结直肠癌HT-29细胞周期阻滞和凋亡

Journal of cancer research updates Pub Date : 2018-05-07 DOI: 10.6000/1929-2279.2018.07.02.4

Wu-Ming Qin, Kun Wang, Jia-Rong Huang, Xiao-Long Mei, Zhi Shi

引用次数: 1

HepG2 Attenuation Induced by RNase A Modulates Gene Profiling and Immunophenotypic Characterization of Some Immune Cells Operating in Cancer Vaccine RNase A诱导的HepG2衰减调节肿瘤疫苗中某些免疫细胞的基因谱和免疫表型特征

Journal of cancer research updates Pub Date : 2018-02-28 DOI: 10.6000/1929-2279.2018.07.01.3

F. Hamid, M. Singer, Mahmoud N. El-Rouby, M. M. Said, R. Tabashy, M. El-Houseini

{"title":"HepG2 Attenuation Induced by RNase A Modulates Gene Profiling and Immunophenotypic Characterization of Some Immune Cells Operating in Cancer Vaccine","authors":"F. Hamid, M. Singer, Mahmoud N. El-Rouby, M. M. Said, R. Tabashy, M. El-Houseini","doi":"10.6000/1929-2279.2018.07.01.3","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.01.3","url":null,"abstract":"Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer death. Attempts to induce an effective immune response against cancer by immunotherapeutic intervention, including activation of dendritic cells (DCs), were established. The present study was undertaken to investigate the attenuation of HepG2 cells using ribonuclease enzyme A (RNase A) as a possible biological factor to sensitize allogenic DCs and lymphocytes isolated from Egyptian HCC patients. Attenuation of HepG2 cells resulted in a significant increase in activated DC and T-lymphocyte markers, upregulation of CD44 gene expression and increased lactate dehydrogenase as well as interleukin-12 levels. In contrast, a significant decrease in matureDCs, B-cells, T-helper, cytotoxic T-cells, and NK-cells, as well as LMP-2 gene expression was recorded. In conclusion, the attenuation of HepG2 cells with RNase A and subsequent pulsation to allogenic DCs and lymphocytes caused a differential immune response. Further studies are recommended to explain the role of RNase A in modulating antigen expression on the tumor cell surface.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 1","pages":"27-34"},"PeriodicalIF":0.0,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44764326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of Kinetics and Efficacy of Anti-Cancer via Oxygen-Enhanced Photodynamic Therapy 氧增强光动力疗法抗癌动力学及疗效分析

Journal of cancer research updates Pub Date : 2018-02-02 DOI: 10.6000/1929-2279.2018.07.01.2

Jui-Teng Lin, Kuo-Ti Chen, Hsia-Wei Liu

{"title":"Analysis of Kinetics and Efficacy of Anti-Cancer via Oxygen-Enhanced Photodynamic Therapy","authors":"Jui-Teng Lin, Kuo-Ti Chen, Hsia-Wei Liu","doi":"10.6000/1929-2279.2018.07.01.2","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.01.2","url":null,"abstract":"Photodynamic therapy (PDT has been widely used in many medical applications. PDT for anti-cancer is one of the clinically important subjects. This study will analyze the photochemical kinetics and the efficacy of anti-cancer via the critical factors including: the concentrations of photosensitizers and oxygen in the treated target, the exposure time, intensity and does (energy) of the light applied to the target. To achieve high efficacy, one requires the oxygen source term to re-supply the depletion of oxygen and photosensitizers. Higher light intensity has faster rising curve of the efficacy, but it reaches the same steady-state value as that of low intensity. The efficacy follows the Bunsen-Roscoe law (BRL) of reciprocity only when there is no oxygen source term. Higher initial concentration of oxygen and photosensitizers, C 0 , always provide higher efficacy. To achieve the same efficacy, minimum dose and/or less exposure time for accelerated procedure may be achieved by using a higher intensity (but same dose) for the case of P=0. However, with P>0, higher intensity requires a higher fluence to achieve the same efficacy and it does not follow the BRL reciprocity law.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 1","pages":"21-26"},"PeriodicalIF":0.0,"publicationDate":"2018-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41642971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Perioperative Effects of Surgery, Anesthesia and Analgesics Associated with Cancer Progression: A Review 外科、麻醉和镇痛药对癌症进展的围手术期影响：综述

Journal of cancer research updates Pub Date : 2018-02-02 DOI: 10.6000/1929-2279.2018.07.01.1

Keishla M. García, K. M. Flores, A. Falcón, Charlynne De Jesus, L. Rio, Laura C. Rivera, M. Marquez, S. Ortiz, Gretchen Sandoval, Alejandro Ruiz, Fabiola Rodriguez, Frances L. González, K. Cintrón, Miguel J. Berdiel, J. Duconge, M. Santiago, Ines Alfaro, Michael J. González

{"title":"Perioperative Effects of Surgery, Anesthesia and Analgesics Associated with Cancer Progression: A Review","authors":"Keishla M. García, K. M. Flores, A. Falcón, Charlynne De Jesus, L. Rio, Laura C. Rivera, M. Marquez, S. Ortiz, Gretchen Sandoval, Alejandro Ruiz, Fabiola Rodriguez, Frances L. González, K. Cintrón, Miguel J. Berdiel, J. Duconge, M. Santiago, Ines Alfaro, Michael J. González","doi":"10.6000/1929-2279.2018.07.01.1","DOIUrl":"https://doi.org/10.6000/1929-2279.2018.07.01.1","url":null,"abstract":"One of the most common treatments available for cancer patients is surgical removal of the malignant tumor; its long-term implications, however, are still little-known. The purpose of this review is to look at the perioperative effects and determine if there is any correlation between surgery, anesthetics and analgesics, and cancer progression, in the form of cancerous tumor growth and progression and patient survival, within the Puerto Rican population. A retrospective literature review was conducted. Current data suggest that surgery is associated with an increase in cancer proliferation and metastasis, for various reasons such as angiogenesis enhancement and bloodstream migration. Also, it was found that some anesthetics and analgesics have been associated with cancer progression, based on the peri- and postoperative immune status of the patient. Thiopental, ketamine, isoflurane, halothane and some opioids were positively correlated with cancer progression given their role in immunosuppression; while propofol, lidocaine, ropivacaine and bupivacaine were negatively correlated with tumor progression given their immune enhancement. Others, like sevoflurane, nitrous oxide, and etomidate showed inconclusive correspondence. Therefore, it was concluded that immune system boosting anesthetics and analgesics can reduce cancer progression in a patient that has undergone surgical resection. For further research and since the available data are not extensive, other variables such as age, sex, stressors and comorbidities could be considered to better understand the mechanism in which the chemicals hereby studied can cause cancer progression.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"7 1","pages":"1-20"},"PeriodicalIF":0.0,"publicationDate":"2018-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47084382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0